Masonglory, INLIF and Apimeds Lead Small-Cap Gainers on September 25
Key Facts
Masonglory (MSGY) closed at $8.07 on September 25, up 309.6% from the previous session's $1.97 close, after trading as high as $11.42. The company filed no new disclosure that day; its latest filing, on September 24, reported that Chief Executive Tsz Tun Tse had resigned for personal reasons and that Jinyu Xie had been re-designated chief executive and co-chairman. Financial Modeling Prep linked the move to renewed attention on the share swap agreement Masonglory signed on August 12 to acquire 20% of Beta Beteiligungs und Besitz GmbH, an Austrian distributor of construction materials, principally bathtubs, hot tubs and swim spas, in exchange for 1,377,000 new Class A shares.
INLIF (INLF) closed at $5.10 on September 25, up 72.9% from $2.95, after opening at $6.25. After the market closed on September 24, the maker of manipulator arms for injection molding machines reported that net revenue for the first half of fiscal 2026, ended June 30, rose 26.01% to $12.94 million, that its gross margin widened to 35.95% from 17.50%, and that it earned net income of $1.01 million against a net loss of $1.98 million a year earlier. Its newly launched intelligent equipment business contributed $3.36 million, or 25.97% of revenue.
Apimeds Pharmaceuticals US (APUS) closed at $7.25 on September 25, up 47.4% from $4.92, extending a 114.8% gain on September 24. Before the market opened on September 24, the company said its subsidiary MindWave Innovations had signed a 12-month technology services agreement with Singapore-based AQUAE Holdings to design, build, host and support AQUAEChain, a platform for insured ALCI Credits, in return for software development and technology service fees.